Castleark Management’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $9.72M | Sell |
48,696
-18,040
| -27% | -$3.57M | 0.32% | 61 |
|
|
2025
Q4 | $12.6M | Buy |
66,736
+2,060
| +3% | +$396K | 0.37% | 52 |
|
|
2025
Q3 | $11.5M | Buy |
+64,676
| New | +$9.61M | 0.32% | 54 |
|
|
2025
Q2 | – | Sell |
-66,463
| Closed | -$6.99M | – | 313 |
|
|
2025
Q1 | $6.99M | Buy |
66,463
+1,350
| +2% | +$153K | 0.24% | 73 |
|
|
2024
Q4 | $6.98M | Sell |
65,113
-2,810
| -4% | -$318K | 0.24% | 88 |
|
|
2024
Q3 | $6.8M | Buy |
67,923
+6,560
| +11% | +$660K | 0.28% | 80 |
|
|
2024
Q2 | $5.17M | Sell |
61,363
-550
| -0.9% | -$43.8K | 0.21% | 112 |
|
|
2024
Q1 | $4.53M | Sell |
61,913
-789
| -1% | -$58.2K | 0.19% | 130 |
|
|
2023
Q4 | $4.48M | Buy |
62,702
+23,520
| +60% | +$1.39M | 0.2% | 124 |
|
|
2023
Q3 | $2.35M | Sell |
39,182
-820
| -2% | -$54K | 0.12% | 160 |
|
|
2023
Q2 | $2.88M | Buy |
+40,002
| New | +$3M | 0.13% | 152 |
|
|
2020
Q3 | – | Sell |
-38,656
| Closed | -$2.7M | – | 365 |
|
|
2020
Q2 | $2.7M | Buy |
+38,656
| New | +$2.45M | 0.12% | 163 |
|
|
2019
Q1 | – | Sell |
-63,759
| Closed | -$5.4M | – | 382 |
|
|
2018
Q4 | $5.4M | Sell |
63,759
-67,366
| -51% | -$7.18M | 0.23% | 134 |
|
|
2018
Q3 | $22.5M | Sell |
131,125
-16,696
| -11% | -$2.52M | 0.65% | 34 |
|
|
2018
Q2 | $19.1M | Buy |
147,821
+13,528
| +10% | +$1.51M | 0.59% | 38 |
|
|
2018
Q1 | $13.8M | Sell |
134,293
-26,552
| -17% | -$2.63M | 0.44% | 66 |
|
|
2017
Q4 | $13.7M | Sell |
160,845
-16
| -0% | -$1.39K | 0.41% | 83 |
|
|
2017
Q3 | $13.7M | Buy |
160,861
+34,737
| +28% | +$2.75M | 0.43% | 71 |
|
|
2017
Q2 | $9.55M | Buy |
+126,124
| New | +$8.82M | 0.31% | 108 |
|
|
2016
Q4 | – | Sell |
-205,339
| Closed | -$13.1M | – | 404 |
|
|
2016
Q3 | $13.1M | Sell |
205,339
-71,018
| -26% | -$5.21M | 0.4% | 62 |
|
|
2016
Q2 | $20.6M | Sell |
276,357
-65,965
| -19% | -$4.9M | 0.66% | 39 |
|
|
2016
Q1 | $22.9M | Buy |
342,322
+11,181
| +3% | +$680K | 0.71% | 40 |
|
|
2015
Q4 | $22.4M | Sell |
331,141
-5,467
| -2% | -$338K | 0.67% | 36 |
|
|
2015
Q3 | $18M | Sell |
336,608
-15,283
| -4% | -$927K | 0.58% | 38 |
|
|
2015
Q2 | $22.1M | Buy |
351,891
+107,033
| +44% | +$5.84M | 0.59% | 40 |
|
|
2015
Q1 | $11.8M | Buy |
+244,858
| New | +$9.38M | 0.28% | 108 |
|
|
2014
Q4 | – | Sell |
-379,344
| Closed | -$15.9M | – | 372 |
|
|
2014
Q3 | $15.9M | Buy |
379,344
+217,015
| +134% | +$7.2M | 0.45% | 47 |
|
|
2014
Q2 | $6.31M | Sell |
162,329
-217,015
| -57% | -$8.81M | 0.17% | 137 |
|
|
2014
Q1 | $15.9M | Buy |
379,344
+39,256
| +12% | +$1.64M | 0.45% | 47 |
|
|
2013
Q4 | $11.2M | Buy |
+340,088
| New | +$11.1M | 0.32% | 53 |
|
|
2013
Q3 | – | Sell |
-312,721
| Closed | -$7.3M | – | 374 |
|
|
2013
Q2 | $7.3M | Buy |
+312,721
| New | +$5.62M | 0.24% | 49 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
Castleark Management's LGND Position: Q1 2026 in Review
Castleark Management reduced its Ligand Pharmaceuticals (LGND) stake by 27% in Q1 2026, selling an estimated $3.57M and leaving 48,696 shares worth $9.72M. The position accounts for 0.32% of the portfolio, ranked #61.
Castleark Management first reported a position in LGND in Q2 2013 and has held it in 31 quarters since. The position peaked at $22.9M in Q1 2016. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- Castleark Management held 48,696 shares of Ligand Pharmaceuticals worth $9.72M as of Q1 2026.
- Castleark Management sold 18,040 Ligand Pharmaceuticals shares in Q1 2026, an estimated $3.57M.
- Ligand Pharmaceuticals made up 0.32% of Castleark Management's portfolio in Q1 2026, its #61 holding.
- Castleark Management first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 31 quarters since.
- Castleark Management's Ligand Pharmaceuticals position peaked at $22.9M in Q1 2016.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on Castleark Management's 13F filing for Q1 2026, filed 15 May 2026.